Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration
Ophthalmologica · 2021 · 244 (2) · 93-101
DOI: 10.1159/000513048 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Ophthalmologica, online erschienen am 16.11.2020. Verfasst von Ramin Tadayoni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Université de Paris, Ophthalmology Department, AP-HP, Hôpital Lariboisière, Paris, France. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Macular Degeneration. Die Arbeit wurde bisher 146-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular age-related macular degeneration (nAMD).
Purpose
To review the milestones in the molecular and clinical development of brolucizumab, the first single-chain antibody fragment (scFv) designed specifically for intraocular use in humans.
Methods
In this article, we summarize the preclinical and current clinical evidence of brolucizumab administration with an overview of the other treatment regimens and additional indications under investigation.
Results
The unique molecular design of brolucizumab led to a low molecular weight of only 26 kDa, allowing for a concentrated molar dose of 1 intravitreal injection compared with other anti-VEGF agents. Phase I and II clinical trial outcomes validated the efficacy of brolucizumab in the treatment of nAMD with signals of a more durable treatment effect. The pivotal phase III trials, HAWK and HARRIER, which included a total of 1,817 patients, established that brolucizumab can be administered every 3 months while maintaining disease control.
Conclusions
The preclinical and clinical data on brolucizumab provide evidence of sustained disease control with longer injection intervals, thus potentially reducing the treatment burden in patients with nAMD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Paris, Ophthalmology Department, AP-HP, Hôpital Lariboisière, Paris, France.
- Hospital General de Catalunya, Barcelona, Spain.
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Pharma AG, Basel, Switzerland, andreas.clemens@novartis.com.
- Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, andreas.clemens@novartis.com.
- Department of Ophthalmology, University of Bonn, Bonn, Germany.
Zitieren
APA
Tadayoni, R., Sararols, L., Weissgerber, G., Verma, R., Clemens, A., & Holz, F. G. (2021). Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica, 244(2), 93-101. https://doi.org/10.1159/000513048
Vancouver
Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG. Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2021;244(2):93-101. doi:10.1159/000513048
BibTeX
@article{Tadayoni2021,
author = {Tadayoni, Ramin and Sararols, Laura and Weissgerber, Georges and Verma, Rohini and Clemens, Andreas and Holz, Frank G},
title = {Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration},
journal = {Ophthalmologica},
year = {2021},
volume = {244},
number = {2},
pages = {93--101},
doi = {10.1159/000513048}
}
EUVIMED